133 related articles for article (PubMed ID: 6379533)
1. [Long-term osteoporosis with multiple fractures as the early monosymptomatic stage of multiple myeloma].
Abbrederis K; Gattringer C; König P; Gastl G
Onkologie; 1984 Jun; 7(3):152-5. PubMed ID: 6379533
[TBL] [Abstract][Full Text] [Related]
2. Marked and sustained improvement of systemic sclerosis following polychemotherapy for coexistent multiple myeloma.
Bachleitner-Hofmann T; Machold K; Knobler R; Drach J; Grumbeck E; Gisslinger H
Clin Exp Rheumatol; 2002; 20(1):85-8. PubMed ID: 11892717
[TBL] [Abstract][Full Text] [Related]
3. [Erythropoietin in multiple myeloma].
Pecherstorfer M; Schmoranzer F; Vesely M; Fortelny A; Baumgartner G
Dtsch Med Wochenschr; 1990 Jul; 115(28-29):1096-9. PubMed ID: 2373040
[TBL] [Abstract][Full Text] [Related]
4. Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.
Kabir AL; Rahman MJ; Begum M; Dipta TF; Baqui MN; Aziz A; Rahman F; Debnath RC; Habib MA
Mymensingh Med J; 2012 Jan; 21(1):114-9. PubMed ID: 22314465
[TBL] [Abstract][Full Text] [Related]
5. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma].
Wutke K; Anger G
Z Gesamte Inn Med; 1983 Dec; 38(23):630-3. PubMed ID: 6689459
[TBL] [Abstract][Full Text] [Related]
6. Multiple complications in multiple myeloma.
Basi S; Schulman G; Fogo AB
Am J Kidney Dis; 2005 Mar; 45(3):619-23. PubMed ID: 15754288
[No Abstract] [Full Text] [Related]
7. Myelomatous effusion with poor response to chemotherapy.
Kim YM; Lee KK; Oh HS; Park SK; Won JH; Hong DS; Park HS; Park JS; Lee DW
J Korean Med Sci; 2000 Apr; 15(2):243-6. PubMed ID: 10803706
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
Montalbán C; Sevilla F; Zapatero A; Blanco L; Sabán J; Serrano M; Serrano Ríos M
Rev Clin Esp; 1985 May; 176(8):392-5. PubMed ID: 3839590
[No Abstract] [Full Text] [Related]
9. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B
J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone].
Montalbán C; Zapatero A; Blanco L; Sevilla F; García Laraña J; Odriozola J
Sangre (Barc); 1984; 29(6):993-9. PubMed ID: 6549486
[No Abstract] [Full Text] [Related]
11. A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma.
Nagura E; Ichikawa A; Kamiya O; Kato R; Utsumi M; Tanaka M; Takeyama H; Shimizu K; Kobayashi M; Naito K; Nishiwaki H; Mizuno H; Hirabayashi N; Nitta M; Kato Y; Shibata T; Hotta T; Kawashima K; Saito H
Cancer Chemother Pharmacol; 1997; 39(4):279-85. PubMed ID: 9025767
[TBL] [Abstract][Full Text] [Related]
12. Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial.
Scheithauer W; Cortelezzi A; Fritz E; Kührer I; Polli E; Baldini L; Ludwig H
J Biol Response Mod; 1989 Apr; 8(2):109-15. PubMed ID: 2659740
[TBL] [Abstract][Full Text] [Related]
13. Dementia improvement with cytotoxic chemotherapy. A case of Alzheimer disease and multiple myeloma.
Keimowitz RM
Arch Neurol; 1997 Apr; 54(4):485-8. PubMed ID: 9109751
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
Colović MD; Janković GM; Nikolov VS; Suvajdzić ND; Miletić VD
Haematologia (Budap); 1994; 26(2):91-6. PubMed ID: 7890267
[TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy of multiple myeloma].
Golenkov AK
Sov Med; 1991; (3):43-6. PubMed ID: 1882290
[No Abstract] [Full Text] [Related]
16. [Polychemotherapy versus melphalan-prednisone in multiple myeloma].
Leoni P; Salvi A; Brianzoni MF; Centurioni R; Montillo M; Olivieri A
G Clin Med; 1986 Dec; 67(5-6):291-6. PubMed ID: 3609590
[No Abstract] [Full Text] [Related]
17. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Boccadoro M; Marmont F; Tribalto M; Avvisati G; Andriani A; Barbui T; Cantonetti M; Carotenuto M; Comotti B; Dammacco F
J Clin Oncol; 1991 Mar; 9(3):444-8. PubMed ID: 1999714
[TBL] [Abstract][Full Text] [Related]
18. Autopsy-documented cure of multiple myeloma 14 years after M2 chemotherapy.
van Hoeven KH; Reed LJ; Factor SM
Cancer; 1990 Oct; 66(7):1472-4. PubMed ID: 2207998
[TBL] [Abstract][Full Text] [Related]
19. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients].
Bladé J; Urbano A; López Guillermo A; Rozman M; Rovira M; Montserrat E; Rozman C
Sangre (Barc); 1990 Apr; 35(2):93-7. PubMed ID: 2363100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]